Clinical trial shows preliminary efficacy of all-oral regimen for patients with lenalidomide-refractory multiple myeloma

Early results from the Clinical Trials Alliance in Oncology randomized clinical trials of adults with relapsing multiple myeloma in frontline treatment of lenalidomide show that adding ixazomib (Ninlaro┬«) to pomalidomide and dexamethasone as part of second-line treatment prolonged the time patients lived before being treated. . Exacerbation of disease (progression-free survival) compared to patients who … Read more